Summary
Vertex Pharmaceuticals Inc. reported robust financial performance for the first quarter of 2020, driven significantly by the launch and strong uptake of its new cystic fibrosis (CF) therapy, TRIKAFTA, which received U.S. FDA approval in October 2019. Total revenues surged by 76% year-over-year to $1.52 billion, with product revenues nearly doubling to $1.51 billion, primarily due to TRIKAFTA's contribution. This revenue growth outpaced the increase in operating expenses, leading to a substantial 160% rise in income from operations and a remarkable 124% increase in net income to $602.8 million, or $2.29 per diluted share. The company also highlighted its strategic focus on expanding its CF franchise, aiming for treatments covering up to 90% of CF patients, and advancing its pipeline in other serious diseases like AAT deficiency, APOL1-mediated kidney diseases, and pain, as well as exploring genetic therapies. Despite the evolving COVID-19 landscape, Vertex reaffirmed its commitment to maintaining its supply chain and patient access to its medicines, though some R&D activities experienced delays. The company maintained a strong liquidity position with over $4.19 billion in cash, cash equivalents, and marketable securities.
Financial Highlights
50 data points| Revenue | $1.52B |
| Cost of Revenue | $162.50M |
| Gross Profit | $1.35B |
| R&D Expenses | $448.53M |
| SG&A Expenses | $182.26M |
| Operating Expenses | $794.88M |
| Operating Income | $720.22M |
| Interest Expense | $14.14M |
| Net Income | $602.75M |
| EPS (Basic) | $2.32 |
| EPS (Diluted) | $2.29 |
| Shares Outstanding (Basic) | 259.81M |
| Shares Outstanding (Diluted) | 263.51M |
Key Highlights
- 1Total revenues increased by 76% to $1.52 billion in Q1 2020 compared to Q1 2019.
- 2Product revenues grew significantly by 77% to $1.51 billion, primarily driven by the launch of TRIKAFTA.
- 3Net income more than doubled, increasing by 124% to $602.8 million, resulting in diluted EPS of $2.29.
- 4Research and development expenses increased by 32% to $448.5 million, reflecting continued investment in pipeline advancement.
- 5The company maintained a strong liquidity position with $4.19 billion in cash, cash equivalents, and marketable securities as of March 31, 2020.
- 6Vertex is expanding its CF therapy coverage and advancing pipeline candidates in other serious disease areas.
- 7Despite COVID-19, the company stated no impact on its supply chain or demand for medicines, though some R&D activities were delayed.